Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 9
2013 7
2014 13
2015 10
2016 6
2017 11
2018 18
2019 17
2020 13
2021 12
2022 8
2023 8
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 31643466

99 results

Results by year

Filters applied: . Clear all
Page 1
Abiraterone.
[No authors listed] [No authors listed] 2023 Mar 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Mar 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643466 Free Books & Documents. Review.
Antiandrogens.
[No authors listed] [No authors listed] 2014 Jun 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2014 Jun 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643810 Free Books & Documents. Review.
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F. Clarke N, et al. Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4. Lancet Oncol. 2018. PMID: 29880291 Clinical Trial.
Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
Kobayashi K, Okuno N, Arai G, Nakatsu H, Maniwa A, Kamiya N, Satoh T, Kikukawa H, Nasu Y, Uemura H, Nakashima T, Mikami K, Iinuma M, Tanabe K, Furukawa J, Kobayashi H. Kobayashi K, et al. Jpn J Clin Oncol. 2021 Apr 1;51(4):544-551. doi: 10.1093/jjco/hyaa225. Jpn J Clin Oncol. 2021. PMID: 33324967 Free PMC article. Clinical Trial.
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Yanagisawa T, Kimura T, Mori K, Suzuki H, Sano T, Otsuka T, Iwamoto Y, Fukuokaya W, Miyajima K, Enei Y, Sakanaka K, Matsukawa A, Onuma H, Obayashi K, Tsuzuki S, Hata K, Shimomura T, Miki J, Egawa S. Yanagisawa T, et al. Prostate. 2022 Jan;82(1):3-12. doi: 10.1002/pros.24243. Epub 2021 Sep 24. Prostate. 2022. PMID: 34559410
99 results